- ECTRIMS provides guidance to the medical community dealing with the challenges brought on by COVID-19, especially regarding the treatment of patients with MS and other autoimmune diseases.
- ECTRIMS recommends to consult recommednations and guidelines issued by your national and local health authorities.
- Executive Committee highlights recent release by MSIF on the topic of vaccination for MS patients
Dear Colleagues
The global spread of COVID-19 has had a deep impact on our daily tasks and we are currently experiencing a challenging time in terms of the treatment of our patients with MS as well as other autoimmune diseases. The current circumstances are very concerning and also unclear for MS patients in the context of COVID-19 infections. In such a situation, it is important to receive up-to-date information on the newest developments. Many National MS Societies have published statements for patients with MS as well as for neurologists. We recommend to
consult recommendations and guidelines issued by your national and local health authorities.
ECTRIMS would like to make everybody aware of the recent statement published by MSIF. The latest version was updated on 13 January and also includes information on the topic of vaccination. This patient oriented statement can be a helpful source of information for patients living with MS.
Furthermore, ECTRIMS strongly encourages you to document all patients with COVID-19 infections in one of the available registries. The more patient data is documented in the registries, the more information we can gain from them. We would like to inform that ECTRIMS is leading a European Consensus on Vaccination in patients with MS. Its aim is to provide guidance and
best care recommendations on this topic – with a special focus on SARSCoV-2 vaccines. The forthcoming digital ECTRIMS focused workshop “Risk of Infections in MS DMT’s” will also provide an expert forum to inform the consensus. We wish you all the best for this challenging time and hope that you will stay healthy.
With warm regards,
The ECTRIMS Executive Committee
About ECTRIMS
For nearly 30 decades, ECTRIMS has been committed to its mission of facilitating communication, creating synergies and promoting and enhancing research and learning among professionals for the ultimate benefit of people affected by multiple sclerosis. ECTRIMS works with researchers and clinicians of its member countries and with other organisations that share similar missions and objectives on a worldwide scale, creating networking and collaboration opportunities. The ultimate goal of ECTRIMS is to improve basic and clinical research and clinical outcomes in MS.
Download the press release here.